This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Brookdale's 37-Month Growth Streak: Is BKD Stock a Safe Bet?
by Zacks Equity Research
BKD's weighted average occupancy for November grows 10 bps sequentially.
Community Health Unit Northwest Urgent Closes Arizona Buyouts
by Zacks Equity Research
CYH's acquisition expands Northwest Healthcare arm's network to more than 80 care sites.
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CareDx (CDNA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Select Medical Distributes Concentra Shares to Shareholders
by Zacks Equity Research
By separating from Concentra, which specializes in occupational health services, SEM can better allocate resources to its primary segments.
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 49.9% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tenet Healthcare Partners With Commure for Ambient AI Platform
by Zacks Equity Research
THC actively invests in selected AI-enabled technologies, which are expected to enhance the clinical and administrative workflow and efficiency.
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for CareDx (CDNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Are Medical Stocks Lagging CareDx (CDNA) This Year?
by Zacks Equity Research
Here is how CareDx (CDNA) and Doximity (DOCS) have performed compared to their sector so far this year.
DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal
by Zacks Equity Research
The DOJ suggests that UNH's acquisitions reflect a strategy of buying competitors rather than competing directly, potentially giving it control over multiple markets.
Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips
by Zacks Equity Research
CI reaffirms its 2024 outlook, projecting full-year adjusted EPS to be a minimum of $28.40.
Pediatrix Medical Stock Soars 30.5% Since Q3 Earnings Beat
by Zacks Equity Research
MD expects transformational and restructuring-related expenses to be $48 million in 2024.
Teladoc Health Q3 Loss Narrows on Strong Integrated Care Unit
by Zacks Equity Research
TDOC expects 2024 U.S. Integrated Care Members to remain within 93.5-94.5 million.
Humana Q3 Earnings Beat on Growing Premiums & Cost Management
by Zacks Equity Research
Better-than-expected Medicare Advantage membership aids HUM's third-quarter results.
Encompass Health Opens 9th Hospital in SC: More in the Pipeline?
by Zacks Equity Research
This new facility is part of EHC's continued strategy to meet the rising demand for rehabilitative services.
Select Medical Rises 50.2% YTD: Take Profits or Bet on More Gains?
by Zacks Equity Research
SEM's profitability is being impacted by rising costs and expenses.
Teladoc Stock Rises 12% as Jefferies Boosts Price Target on BetterHelp
by Zacks Equity Research
TDOC's stock benefits from improving web traffic in its BetterHelp platform.
Community Health's Arm Northwest Urgent Buys 10 Arizona Facilities
by Zacks Equity Research
CYH expects the acquisition from Carbon Health to be completed in the fourth quarter of 2024.
Pediatrix Medical Up 45.8% in 3 Months: Is it Too Late to Jump In?
by Zacks Equity Research
MD remains one of the best-positioned pediatric service providers with favorable valuation to achieve margin improvement.
Beat the Market Like Zacks: CareDx, Fair Isaac, 3M in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 292.31% and 37.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.